SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

GUTIERREZ-HERMOSILLO, H. et al. Metoclopramida, factor de riesgo para hiperglucemia postprandial en diabetes tipo 2. Nutr. Hosp. [online]. 2012, vol.27, n.4, pp.1267-1271. ISSN 0212-1611.  http://dx.doi.org/10.3305/nh.2012.27.4.5607.

    1. Summary of revisions for the 2007 clinical practice recommendations. Diabetes Care 2007; 30 (Suppl. 1): S3. [ Links ]

    2. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med 2004; 21 (3): 208-13. [ Links ]

    3. Estadísticas de Mortalidad. Secretaría de Salud. México, 2000. Disponible en: http://www.ssa.gob.mx/apps/htdocs/estadisticas/estadisticas/motalidad/mortalidad2000.html [ Links ]

    4. Alexanderson Rosas G, González Chávez A, Rosas Carrasco O, Camacho Aguilera J, Caba Molina D. Estado postprandial. Med Int Mex 2002; 18 (3): 137-45. [ Links ]

    5. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29 (5): 1130-9. [ Links ]

    6. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2): 233-40. [ Links ]

    7. Veglio M, Bruno G, Borra M, Macchia G, Bargero G, D'Errico N, Pagano GF, Cavallo-Perin P. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 2002; 251 (4): 317-24. [ Links ]

    8. Jens JH, Urskov C. The Incretin Aproach for Diabetes Treatment. Diabetes 2004; 53 (3): 197-203. [ Links ]

    9. Camilleri M. Diabetic gastroparesis. N Engl J Med 2007; 356(8): 820-830. [ Links ]

    10. Chaikomin R, Doran S, Jones KL, Feinle-Bisset C, O'Donovan D, Rayner CK, Horowitz M. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005; 289 (3): E504-7. [ Links ]

    11. O'Donovan DG, Doran S, Fienle-Bisset C, Jones KL, Meyer JH, Wishart JM, Morris HA, Horowitz M. Effect of variations in Small Intestinal Glucose, Insulin, and Incretin Hormones in Healthy Subjects and Type 2 Diabetes. J Clin Edocrinol Metabol 2004; 89 (7): 3431-3445. [ Links ]

    12. Drenth JPH, Engels LGJB: Diabetic gasttroparesis: a critical reappraisal of new treatment strategies. Drugs 1992; 44: 537-553. [ Links ]

    13. Horowitz M, O'Donovan KL, Jones C, Feinle C, Rayner, Samsom. Gastric emptying:in diabetes clinical significance and treatment. Diabetic Med 2002; 19 (3): 177-194. [ Links ]

    14. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A, Yamauchi A. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007; 105 (2): c54-7. [ Links ]

    15. Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M. Plasma glucose Levels throughout the day and HbA (1c) interrelationships in type 2 diabetes. diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001; 24 (12): 2023-9. [ Links ]

    16. Bonora E, Corrao G, Bagnardi V, Ceriello A, Comaschi M, Montanari P, Meigs JB. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006; 49 (5): 846-54. [ Links ]

    17. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24 (7): 1264-9. [ Links ]

    18. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, Horowitz M. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010; 95 (1): 215-21. [ Links ]

    19. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in tipe 2 diabetes. Regul Pept 2008; 151 (1-3): 123-9. [ Links ]

    20. Lehmann R, Honegger RA, Feinle C, Fried M, Spinas GA, Schwizer W. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. a pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003; 111 (5): 255-61. [ Links ]

    21. Horowitz M, Jones KL, Harding PE, Wishart JM. Relationship between the effects of cisapride on gastric emptying and plasma glucose concentration in diabetic gastroparesis. Digestion 2002; 65 (1): 41-6. [ Links ]

    22. Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WF, Lembcke B. Long-term cisaprida treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002; 16 (7): 1341-6. [ Links ]

    23. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erytromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54 (7): 2212-2218. [ Links ]

    24. MacLaren R, Patrick WD, Hall RI, Rocker GM, Whelan GJ, Lima JJ. Comparison of cisapride and metoclopramida for facilitating gastric emptying and improving tolerance to intra-gastric enteral nutrition in critically ill, mechanically ventilated adults. Clin Ther 2001; 23 (11): 1855-66. [ Links ]